EN001 ( DrugBank: - )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 10 | シャルコー・マリー・トゥース病 | 1 |
| 113 | 筋ジストロフィー | 1 |
10. シャルコー・マリー・トゥース病
臨床試験数 : 41 / 薬物数 : 46 - (DrugBank : 9) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 15
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05333406 (ClinicalTrials.gov) | February 22, 2022 | 6/1/2022 | Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A | Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A | Charcot-Marie-Tooth Disease, Type IA | Drug: EN001 | ENCell | NULL | Completed | 19 Years | 75 Years | All | 9 | Phase 1 | Korea, Republic of |
113. 筋ジストロフィー
臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05338099 (ClinicalTrials.gov) | January 18, 2022 | 6/1/2022 | Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD) | Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD) | Duchenne Muscular Dystrophy | Drug: EN001 | ENCell | NULL | Completed | 2 Years | 18 Years | Male | 7 | Phase 1 | Korea, Republic of |